Glenmark enrols first patient for phase II trial of GBR 500
The company out licensed Vatelizumab (GBR 500) to Sanofi for all indications in 2011
Glenmark has enrolled first patient in a!--more-->…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.